Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Assets (2016 - 2025)

Adma Biologics' Current Assets history spans 14 years, with the latest figure at $466.5 million for Q4 2025.

  • For Q4 2025, Current Assets rose 40.77% year-over-year to $466.5 million; the TTM value through Dec 2025 reached $466.5 million, up 40.77%, while the annual FY2025 figure was $466.5 million, 40.77% up from the prior year.
  • Current Assets reached $466.5 million in Q4 2025 per ADMA's latest filing, up from $402.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $466.5 million in Q4 2025 to a low of $171.4 million in Q2 2021.
  • Average Current Assets over 5 years is $280.0 million, with a median of $268.3 million recorded in 2022.
  • Peak YoY movement for Current Assets: decreased 4.95% in 2023, then skyrocketed 40.77% in 2025.
  • A 5-year view of Current Assets shows it stood at $208.7 million in 2021, then increased by 29.55% to $270.4 million in 2022, then fell by 4.95% to $257.0 million in 2023, then increased by 28.95% to $331.4 million in 2024, then surged by 40.77% to $466.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Current Assets are $466.5 million (Q4 2025), $402.7 million (Q3 2025), and $399.6 million (Q2 2025).